2. Search Result
Search Result
Results for "

glucagon receptor antagonist

" in MedChemExpress (MCE) Product Catalog:

47

Inhibitors & Agonists

15

Peptides

2

Inhibitory Antibodies

1

Natural
Products

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P0264
    Exendin(9-39) amide
    Maximum Cited Publications
    34 Publications Verification

    Avexitide

    		 GLP Receptor Metabolic Disease
    Exendin(9-39) amide (Avexitide) is a glucagon-like peptide-1 (GLP-1) antagonist that competes with endogenous GLP-1 for binding to GLP-1 receptors, thereby antagonizing the effects of excess GLP-1 secretion. Exendin(9-39) amide can be used to study postoperative hypoglycemia (PBH) .
    Exendin(9-39) amide
  • HY-50663
    MK 0893
    5+ Cited Publications

    		 GCGR Metabolic Disease
    MK 0893 is a potent and selective glucagon receptor antagonist with an IC50 of 6.6 nM.
    MK 0893
  • HY-19904
    Adomeglivant
    4 Publications Verification

    LY2409021

    		 GCGR Metabolic Disease
    Adomeglivant (LY2409021) is a potent, selective glucagon receptor (GluR) allosteric antagonist. Adomeglivant is widely used in the research for type 2 diabetes mellitus .
    Adomeglivant
  • HY-P1141
    GLP-1(9-36)amide

    		GCGR Metabolic Disease
    GLP-1(9-36)amide is a major metabolite of glucagon-like peptide-1-(7-36) amide formed by the enzyme dipeptidyl peptidase-4 (DPP-4). GLP-1(9-36)amide acts as an antagonist to the human pancreatic GLP-1 receptor .
    GLP-1(9-36)amide
  • HY-12525
    LGD-6972

    		GCGR Metabolic Disease
    LGD-6972 is a selective and orally active glucagon receptor antagonist. LGD-6972 has the potential for type 2 diabetes research .
    LGD-6972
  • HY-101116
    GLP-1R Antagonist 1
    5 Publications Verification

    		 GCGR Metabolic Disease
    GLP-1R Antagonist 1 (compound 5d) is an orally active, CNS penetrant and non-competitive antagonist of glucagon-like peptide 1 receptor (GLP-1R), with an IC50 of 650 nM .
    GLP-1R Antagonist 1
  • HY-19947
    PF-06291874
    1 Publications Verification

    glucagon receptor antagonists-4

    		 GCGR Metabolic Disease
    PF-06291874 is a highly potent, non-peptide and orally active glucagon receptor antagonist. PF-06291874 is under the study for type 2 diabetes mellitus (T2DM) .
    PF-06291874
  • HY-P1782
    Calcitonin (8-32), salmon

    		Amylin Receptor Metabolic Disease
    Calcitonin (8-32), salmon is a highly selective Amylin receptor antagonist. Calcitonin (8-32), salmon reverses the Amylin-mediated inhibition of glucose-induced insulin release, but has no effect on either glucagon release or somatostatin release. Calcitonin (8-32), salmon can be used for studies related to β-cell amylin .
    Calcitonin (8-32), salmon
  • HY-103547
    L-168049
    1 Publications Verification

    		 GCGR Metabolic Disease
    L-168049 is a potent, selective, orally active and non-competitive glucagon receptor antagonist with IC50s of 3.7 nM, 63 nM, and 60 nM for human, murine, and canine glucagon receptors, respectively .
    L-168049
  • HY-P10957
    Imapextide

    MBX 1416

    		 GLP Receptor Metabolic Disease
    Imapextide is a glucagon-like peptide-1 (GLP-1) receptor antagonist that can be used in hypoglycemia research .
    Imapextide
  • HY-50159
    Glucagon receptor antagonist-3

    		GCGR Metabolic Disease
    Glucagon receptor antagonist-3 is a highly potent glucagon receptor antagonist.
    Glucagon receptor antagonist-3
  • HY-148844
    GCGR antagonist 2

    		GCGR Metabolic Disease
    GCGR antagonist 2, a Furan-2-carbohydrazide, is an orally active glucagon receptor antagonist. GCGR antagonist 2 binds to hGluR with an Kd value of 2.3 nM, and inhibits rat receptor with an IC50 value of 0.43 nM. GCGR antagonist 2 inhibits glucagon-stimulated glycogenolysis .
    GCGR antagonist 2
  • HY-P99383
    Volagidemab

    REMD-477; AMG-477

    		 GCGR Metabolic Disease
    Volagidemab is an antagonistic glucagon receptor (GCGR) monoclonal antibody (mAb). Volagidemab can be used in the research of type 1 diabetes (T1D) .
    Volagidemab
  • HY-50158
    Glucagon receptor antagonist-2

    		GCGR Metabolic Disease Inflammation/Immunology
    Glucagon receptor antagonist-2 is a glucagon receptor antagonist. Glucagon receptor antagonist-2 functionally inhibits receptor activity via reduced cAMP production. Glucagon receptor antagonist-2 can be used for the research of type 2 diabetes .
    Glucagon receptor antagonist-2
  • HY-10036
    Glucagon receptor antagonist-1

    		GCGR Metabolic Disease
    Glucagon receptor antagonist-1 is a highly potent glucagon receptor antagonist.
    Glucagon receptor antagonist-1
  • HY-106103
    Seglitide

    MK-678; L-363586

    		 Somatostatin Receptor Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
    Seglitide (MK-678) is an orally active, selective SSTR2 agonist and somatostatin analog. Seglitide also acts as a competitive Somatostatin receptor antagonist, with pA2 values of 6.50, 6.24 and 6.09 against SS14, SS25 and SS28, respectively. Seglitide produces only weak, transient inhibition of myocardial contractility in isolated right atria of guinea pigs. Seglitide inhibits glucagon secretion and reduces circulating insulin levels. Seglitide causes a sustained, reversible reduction in elevated systolic blood pressure in streptozotocin (HY-13753)-induced diabetic rats, but exerts no effect on spontaneously hypertensive rats. Seglitide induces membrane hyperpolarization and inhibits electrical excitability. Seglitide induces concentration-dependent contraction and significant desensitization in isolated distal colon of rats. Seglitide can be used in research related to hypertension complicated with insulin-dependent diabetes mellitus .
    Seglitide
  • HY-P1143A
    [Des-His1,Glu9]-Glucagon amide TFA

    		GCGR Metabolic Disease
    [Des-His1,Glu9]-Glucagon amide TFA is a potent and peptide antagonist of the glucagon receptor, with a pA2 of 7.2. [Des-His1,Glu9]-Glucagon amide TFA is potentially useful in the study of the pathogenesis of diabetes .
    [Des-His1,Glu9]-Glucagon amide TFA
  • HY-P2497
    Exendin (5-39)
    1 Publications Verification

    		 GCGR Neurological Disease
    Exendin (5-39) is a potent glucagon-like peptide 1 (GLP-1) receptor antagonist. Exendin (5-39) improves memory impairment in β-amyloid protein-treated rats .
    Exendin (5-39)
  • HY-116930
    S-20928

    		Melatonin Receptor Metabolic Disease
    S-20928 is an antagonist for melatonin receptor through inhibition of binding of melatonin to its receptors. S-20928 enhances the 2-Deoxy-D-glucose (2DG) (HY-13966)-induced increase in blood glucose and glucagon levels in rats brain .
    S-20928
  • HY-P1159A
    [D-p-Cl-Phe6,Leu17]-VIP TFA
    1 Publications Verification

    		 PACAP Receptor Neurological Disease Inflammation/Immunology
    [D-p-Cl-Phe6,Leu17]-VIP TFA is a competitive and selective antagonist of vasoactive intestinal peptide (VIP) receptor, with the IC50 of 125.8 nM. [D-p-Cl-Phe6,Leu17]-VIP TFA has no activity on glucagon, secretin or GRF receptors .
    [D-p-Cl-Phe6,Leu17]-VIP TFA
  • HY-P1141A
    GLP-1(9-36)amide TFA

    		GCGR Metabolic Disease
    GLP-1(9-36)amide TFA is a major metabolite of glucagon-like peptide-1-(7-36) amide formed by the enzyme dipeptidyl peptidase-4 (DPP-4). GLP-1(9-36)amide TFA acts as an antagonist to the human pancreatic GLP-1 receptor .
    GLP-1(9-36)amide TFA
  • HY-128781
    Glucagon receptor antagonist-5

    		GCGR Metabolic Disease
    Glucagon receptor antagonist-5 (compound 13K) is a potent and orally bioavailable indazole-based glucagon receptor antagonist (Ki=32 nM). Glucagon receptor antagonist-5 has potential for the treatment of type 2 diabetes mellitus (T2DM) .
    Glucagon receptor antagonist-5
  • HY-P1143
    [Des-His1,Glu9]-Glucagon amide

    		GCGR Metabolic Disease
    [Des-His1,Glu9]-Glucagon amide is a potent and peptide antagonist of the glucagon receptor, with a pA2 of 7.2. [Des-His1,Glu9]-Glucagon amide is potentially useful in the study of the pathogenesis of diabetes .
    [Des-His1,Glu9]-Glucagon amide
  • HY-P1159
    [D-p-Cl-Phe6,Leu17]-VIP

    		PACAP Receptor Neurological Disease Inflammation/Immunology
    [D-p-Cl-Phe6,Leu17]-VIP is a competitive and selective antagonist of vasoactive intestinal peptide (VIP) receptor, with the IC50 of 125.8 nM. [D-p-Cl-Phe6,Leu17]-VIP has no activity on glucagon, secretin or GRF receptors .
    [D-p-Cl-Phe6,Leu17]-VIP
  • HY-106103A
    Seglitide acetate

    MK 678 acetate; L 36358 acetate

    		 Somatostatin Receptor Cardiovascular Disease Neurological Disease Metabolic Disease
    Seglitide acetate (MK 678; L 36358 acetate) is a potent, orally active somatostatin receptor 2 (SSTR2) agonist, and also a competitive antagonist of SSTR14, SSTR25, and SSTR28. Seglitide acetate has antihypertensive effects and can inhibit plasma glucagon and growth hormone. Seglitide acetate can be used for research on diabetes .
    Seglitide acetate
  • HY-19374
    BAY-27-9955

    		GCGR Metabolic Disease
    BAY-27-9955 is an orally active non-peptide glucagon receptor antagonist. Bay 27-9955 competitively blocks the interaction of glucagon with the human glucagonreceptor at an IC50 value of 110 nM. BAY-27-9955 can be used for the study of type 2 diabetes .
    BAY-27-9955
  • HY-119739
    Skyrin
    1 Publications Verification

    		 GCGR Metabolic Disease Cancer
    Skyrin is an anthraquinone compound that can be isolated from almond fruit. Skyrin is a receptor-selective glucagon antagonist. Skyrin can inhibit the growth of tumor cells .
    Skyrin
  • HY-P11043
    GEP44

    		GLP Receptor Neuropeptide Y Receptor Arrestin Metabolic Disease
    GEP44 is a peptide biased triple agonist targeting Glucagon-like peptide 1 receptor (GLP-1R), neuropeptide Y1 Receptor (Y1-R), and neuropeptide Y2 Receptor (Y2-R). GEP44 induces Y1-R antagonist-controlled, GLP-1R-dependent stimulation of insulin secretion in both rat and human pancreatic islets by counteracting effects of Y1-R and GLP-1R agonism. GEP44 promotes insulin-independent Y1-R-mediated glucose uptake in muscle tissue and significantly reduces food intake and body weight in diet-induced obese rat models. GEP44 can be used for obesity and type 2 diabetes mellitus research .
    GEP44
  • HY-128103
    Glucagon receptor antagonist-7

    		GCGR Adenylate Cyclase Metabolic Disease
    Glucagon receptor antagonist-7 (Compound 1) is an antagonist for hGCGR, that inhibits the binding of 125I-labeled glucagon to the human glucagon receptor (hGCGR) with IC50 of 181 nM. Glucagon receptor antagonist-7 activates glucagon-stimulated adenylyl cyclase with a KDB of 81 nM in CHO cell. Glucagon receptor antagonist-7 inhibits glucagon-mediated glycogenolysis in human hepatocytes, and lowers blood glucose levels .
    Glucagon receptor antagonist-7
  • HY-118914
    Glucagon receptor antagonist inactive control

    		GCGR
    Glucagon receptor antagonist inactive control (Compound 2) is a compound structurally similar to the glucagon receptor (GCGR) antagonist Glucagon receptor antagonist (Compound 1) but lacks antagonistic activity against glucagon receptor (GCGR). Glucagon receptor antagonist inactive control can be used as a negative control to study mechanisms related to glucagon receptor-mediated signaling pathways .
    Glucagon receptor antagonist inactive control
  • HY-107129
    MK-3577

    		GCGR Metabolic Disease
    MK-3577 is an orally effective glucagon receptor (GCGR) antagonist that reduces hepatic glucose production and lowers blood glucose levels by blocking glucagon receptors on target organs, primarily the liver. Pharmacokinetic analysis in domestic cats indicates that MK-3577 reaches peak levels 3 to 4 hours after oral administration, with a half-life of approximately 15 hours. MK-3577 can be used in diabetes research .
    MK-3577
  • HY-116854
    NNC 92-1687

    		GCGR Metabolic Disease
    NNC 92-1687 is a non-peptide competitive human glucagon receptor antagonist (IC50=20 μM; Ki=9.1 μM). NNC 92-1687 can be used in the research of type 2 diabetes .
    NNC 92-1687
  • HY-180446
    Glucagon receptor antagonist-11

    		GCGR Metabolic Disease
    Glucagon receptor antagonist-11 (Compound 14) is a glucagon receptor antagonist with a pIC50 of 6.677. Glucagon receptor antagonist-10 can be used in studies of glucose homeostasis .
    Glucagon receptor antagonist-11
  • HY-180445
    Glucagon receptor antagonist-10

    		GCGR Metabolic Disease
    Glucagon receptor antagonist-10 (Compound 11) is a glucagon receptor antagonist with a pIC50 of 7.154. Glucagon receptor antagonist-10 can be used in studies of glucose homeostasis .
    Glucagon receptor antagonist-10
  • HY-180444
    Glucagon receptor antagonist-9

    		GCGR Metabolic Disease
    Glucagon receptor antagonist-9 (compound 13) is a potent glucagon receptor antagonist with a pIC50 of 7.000 .
    Glucagon receptor antagonist-9
  • HY-177156
    Glucagon receptor antagonist-8

    		GCGR p38 MAPK Metabolic Disease
    Glucagon receptor antagonist-8 (Compound 1) is a human glucagon receptor and p38 mitogen-activated protein (MAP) kinase antagonist, with IC50s of 0.27 μM and 0.16 μM, respectively .
    Glucagon receptor antagonist-8
  • HY-169707
    GCGR antagonist 3

    		GCGR Metabolic Disease
    GCGR antagonist 3 (example 1) is an antagonist of the glucagon receptor (GCGR) and can be used in diabetes research .
    GCGR antagonist 3
  • HY-12735
    SCH 900822

    		GCGR Metabolic Disease Endocrinology
    SCH 900822 is a potent and selective glucagon receptor (hGCGR) antagonist that blocks the binding of glucagon to its receptor, thereby reducing hepatic glycogenolysis and gluconeogenesis, thereby lowering blood glucose production. SCH 900822 can be used in the study of type 2 diabetes .
    SCH 900822
  • HY-P3608
    [Des-His1,Glu9] Glucagon

    		GCGR Metabolic Disease
    [Des-His1,Glu9] Glucagon is a potent glucagon receptor system peptide antagonist. [Des-His1,Glu9] Glucagon enhances the glucose-stimulated release of insulin from pancreatic islet cells. [Des-His1,Glu9] Glucagon can be used to research diabetes .
    [Des-His1,Glu9] Glucagon
  • HY-12525A
    LGD-6972 sodium

    		GCGR Metabolic Disease
    LGD-6972 sodium is a selective and orally active glucagon receptor antagonist. LGD-6972 sodium has the potential for type 2 diabetes research .
    LGD-6972 sodium
  • HY-19904A
    (+/-)-Adomeglivant

    (+/-)-LY2409021

    		 Endogenous Metabolite Metabolic Disease
    (+/-)-Adomeglivant ((+/-)-LY2409021) is a potent and selective glucagon receptor antagonist with hypoglycemic activity. (+/-)-Adomeglivant is effective in lowering blood sugar levels in both healthy people and people with type 2 diabetes. (+/-)-Adomeglivant is well tolerated by glucagon signaling blockade in patients with type 2 diabetes and significantly reduces fasting and postprandial blood glucose with a concomitant reversible elevation of aminotransferases. Glucagon signaling inhibition by (+/-)-Adomeglivant is a promising potential inhibitory approach for patients with type 2 diabetes and warrants further evaluation of its benefits and risks in longer clinical trials .
    (+/-)-Adomeglivant
  • HY-19904R
    Adomeglivant (Standard)

    LY2409021 (Standard)

    		 GCGR Reference Standards Metabolic Disease
    Adomeglivant (Standard) is the analytical standard of Adomeglivant. This product is intended for research and analytical applications. Adomeglivant (LY2409021) is a potent, selective glucagon receptor (GluR) allosteric antagonist. Adomeglivant is widely used in the research for type 2 diabetes mellitus .
    Adomeglivant (Standard)
  • HY-P3542
    Des His1, Glu8 Exendin-4

    		GCGR Metabolic Disease
    Des His1, Glu8 Exendin-4 is a potent glucagon-like peptide-1 receptor (GLP-1-R) antagonist. Des His1, Glu8 Exendin-4 improves glucose homeostasis by regulating both insulin secretion and glucose production. Des His1, Glu8 Exendin-4 can be used for the research of type 2 diabetic and gastrointestinal .
    Des His1, Glu8 Exendin-4
  • HY-103547R
    L-168049 (Standard)

    		Reference Standards GCGR Metabolic Disease
    L-168049 (Standard) is the analytical standard of L-168049 (HY-103547). This product is intended for research and analytical applications. L-168049 is a potent, selective, orally active and non-competitive glucagon receptor antagonist with IC50s of 3.7 nM, 63 nM, and 60 nM for human, murine, and canine glucagon receptors, respectively .
    L-168049 (Standard)
  • HY-12525B
    LGD 6972 ammonium

    		GCGR Metabolic Disease
    LGD-6972 ammonium is a selective and orally active glucagon receptor antagonist. LGD-6972 ammonium has the potential for type 2 diabetes research .
    LGD 6972 ammonium
  • HY-101116R
    GLP-1R Antagonist 1 (Standard)

    		GCGR Reference Standards Metabolic Disease
    GLP-1R Antagonist 1 (Standard) is the analytical standard of GLP-1R Antagonist 1 (HY-101116). This product is intended for research and analytical applications. GLP-1R Antagonist 1 (compound 5d) is an orally active, CNS penetrant and non-competitive antagonist of glucagon-like peptide 1 receptor (GLP-1R), with an IC50 of 650 nM .
    GLP-1R Antagonist 1 (Standard)
  • HY-P992007
    PF-06293620

    RN909

    		 GCGR Metabolic Disease
    PF-06293620 (RN909) is a monoclonal antibody antagonist of the glucagon receptor. PF-06293620 produces dose-dependent, durable lowering of fasting plasma glucose and reduces HbA1c levels. PF-06293620 can be used for the research of type 2 diabetes mellitus .
    PF-06293620

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: